These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 18230274

  • 1. Pramipexole safely replaces ergot dopamine agonists with either rapid or slow switching.
    Takahashi H, Nogawa S, Tachibana H, Kawamura J, Abe T, Ogino Y, Kashihara K, Hamada T, Kowa H, Pramipexole Switching Study (PraSS) Group.
    J Int Med Res; 2008; 36(1):106-14. PubMed ID: 18230274
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G, Spanish Dopamine Agonists Study Group.
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [Abstract] [Full Text] [Related]

  • 6. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
    Grosset K, Needleman F, Macphee G, Grosset D.
    Mov Disord; 2004 Nov; 19(11):1370-4. PubMed ID: 15389984
    [Abstract] [Full Text] [Related]

  • 7. [Use of dopamine agonists in the treatment of Parkinson's disease].
    Gekht AB.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002 Nov; 102(9):54-8. PubMed ID: 12378886
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
    Junghanns S, Fuhrmann JT, Simonis G, Oelwein C, Koch R, Strasser RH, Reichmann H, Storch A.
    Mov Disord; 2007 Jan 15; 22(2):234-8. PubMed ID: 17094087
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
    JAMA; 1997 Jul 09; 278(2):125-30. PubMed ID: 9214527
    [Abstract] [Full Text] [Related]

  • 12. Switching from pergolide to pramipexole in patients with Parkinson's disease.
    Hanna PA, Ratkos L, Ondo WG, Jankovic J.
    J Neural Transm (Vienna); 2001 Jul 09; 108(1):63-70. PubMed ID: 11261747
    [Abstract] [Full Text] [Related]

  • 13. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.
    Arnold G, Gasser T, Storch A, Lipp A, Kupsch A, Hundemer HP, Schwarz J.
    Arch Gerontol Geriatr; 2005 Jul 09; 41(3):239-53. PubMed ID: 16029905
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
    Lyons KE, Pahwa R.
    Mov Disord; 2009 Oct 30; 24(14):2121-7. PubMed ID: 19768728
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Analysis of pramipexole dose-response relationships in Parkinson's disease.
    Wang Y, Sun SG, Zhu SQ, Liu CF, Liu YM, Di Q, Shang HF, Ren Y, Xiang W, Chen SD.
    Drug Des Devel Ther; 2017 Oct 30; 11():83-89. PubMed ID: 28096656
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.